Specialty branded products
First-line treatment of locally advanced or metastatic Pancreatic adenocarcinoma in patients previously treated with 5-fluorouracil; first-line treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC); Treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy; first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines are clinically contraindicated.
Erlotinib is indicated for the treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer after failure of at least one prior chemotherapy regimen.
Erlotinib in combination with Gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic Pancreatic Cancer.
Capecitabine is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated.